1.3. Tratamiento farmacológico del emocionalismo post-ictus (Allida et al, 2019)

Comparación: Cualquier fármaco frente a placebo/grupo control (imagen obtenida de Allida et al, 2019)

Bibliografía: Allida et al, 2019

Patient or population: emotionalism after stroke

Setting: inpatient

Intervention: pharmaceutical interventions

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of partici- pants	Certainty of the evidence	Comments
	Risk with placebo	Risk with pharmaceutical interventions	(33% 61)	(studies)	(GRADE)	
Emotionalism: 50% reduction in emotionalism	0 per 1000	777 per 1000 (7 to 9)	RR 16.50 (1.07 to 253.40)	19 (1 RCT)	⊕⊝⊝⊝ Very low ^{a, b}	
Emotionalism: improved score on Center for Neurologic Study - Lability Scale (CNS-LS)	643 per 1000	926 per 1000 (611 to 1000)	RR 1.44 (0.95 to 2.19)	28 (1 RCT)	⊕⊕⊝⊝ Low ^a	
Emotionalism: clinician inter- view-based impression of change - improved score	643 per 1000	926 per 1000 (611 to 1000)	RR 1.44 (0.95 to 2.19)	28 (1 RCT)	⊕⊕⊝⊝ Low ^a	
Emotionalism: diminished tearful- ness	292 per 1000	636 per 1000 (425 to 1000)	RR 2.18 (1.29 to 3.71)	164 (3 RCTs)	⊕⊕⊝⊝ Moderate ^c	
Emotionalism: mean scores at end of treatment - Pathologi- cal Laughter and Crying Scale (high score = worse emotional- ism)		MD 8.40 lower (11.56 lower to 5.24 lower)	-	28 (1 RCT)	⊕⊕⊝⊝ Low ^a	Lower score equals better outcomes
Adverse events: 1. death: at end of treatment	0 per 1000	0 per 1000 (2 to 92)	RR 0.59 (0.08 to 4.50)	172 (6 RCTs)	⊕⊕⊕⊝ Moderate ^b	

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; MD: mean difference; OR: odds ratio; RCT: randomised controlled trial; RR: risk ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect